The subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended the emergency use of Covidshield, the COVID-19 vaccine developed by the University of Oxford and drug manufacturer AstraZeneca.
The Covidshield has become the first vaccine to secure a recommendation for emergency use approval in India, but the Drugs Controller General of India (DCGI) will take a final call in this regard.
Sources told Zee News that experts have given their approval for mass immunisation with the vaccine to begin within the next few days.
In phase 1 of vaccination, as many as 1.7 Lakh frontline workers will be vaccinated. In Jammu and Kashmir, 5000 centers have been established for the vaccination of healthcare workers in Phase 1.
The expert panel held its meeting to decide on issuing an approval on the emergency-use authorisation for the vaccines of Serum Institute of India (SII) Oxford-AstraZeneca and Bharat Biotech’s COVID-19 vaccines.
According to sources, the panel`s recommendation has been sent to DCGI VG Somani for approval, which will pave the way for the vaccine`s rollout in India. The rollout will begin on January 6, according to sources.